Bleeding patterns and treatment of von Willebrand disease in children in Assiut
Describes von Willebrand disease and its treatment in children at one hospital.
Plain-language title generated from the registry record
Registry title: Clinical Spectrum and Management of Von Willebrand Disease Among Children in Assiut Governorate
Key facts
- Where
- Asyut, EgyptSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and teenagers with suspected or confirmed von Willebrand disease who live in Assiut Governorate or are treated at Assiut University Children's Hospital.
- Age
- 0 to 18 years
- Sex
- Boys and girls
- Disease stage
- Suspected or confirmed von Willebrand disease (VWD), based on bleeding symptoms, referral for evaluation, or standard lab tests (VWF:Ag, VWF:RCo, Factor VIII activity)
Main reasons for not taking part
- Other inherited bleeding disorders, such as hemophilia A or B, rare clotting factor deficiencies, or platelet function disorders
- Acquired bleeding disorders, such as liver disease, kidney failure, vitamin K deficiency or DIC
- Use of medicines that can disturb clotting tests, such as anticoagulants or antiplatelet drugs
- Incomplete clinical or lab data (past cases)
- Consent refused (new cases)
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 0 and 18 years old?
Source: NCT07410130, who can take part
Where in Egypt
- Assiut UniversityAsyut, EgyptContact: Assiut UniversityNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Assiut University
- Trial code
- NCT07410130
- Record updated
- 13 February 2026
- Original description
Von Willebrand disease (VWD) is the most common inherited bleeding disorder in children. It occurs due to a deficiency or dysfunction of von Willebrand factor, a protein that plays an essential role in blood clotting. Children with VWD may experience frequent nosebleeds, easy bruising, prolonged bleeding after injuries or surgeries, and, in adolescent girls, heavy menstrual bleeding. The severity of symptoms varies widely depending on the type of the disease and the level of the clotting factor.Read full original descriptionShow less
Clinical Spectrum of Von Willebrand Disease Among Children: Frequency, Management, and Outcomes in Assiut Governorate
Von Willebrand disease (VWD) is the most common inherited bleeding disorder in children. It occurs due to a deficiency or dysfunction of von Willebrand factor, a protein that plays an essential role in blood clotting. Children with VWD may experience frequent nosebleeds, easy bruising, prolonged bleeding after injuries or surgeries, and, in adolescent girls, heavy menstrual bleeding. The severity of symptoms varies widely depending on the type of the disease and the level of the clotting factor.
Despite its clinical importance, data about the frequency, clinical presentation, and treatment outcomes of von Willebrand disease among children in Upper Egypt are limited. Early recognition and appropriate management are crucial to prevent complications, reduce hospital visits, and improve quality of life.
This observational study aims to assess the frequency of von Willebrand disease among children attending Assiut University Children's Hospital, describe the different disease subtypes, and evaluate the clinical bleeding patterns and management strategies used in routine practice. The study will include children aged 0-18 years with suspected or confirmed VWD.
Information will be collected from medical records and clinical evaluations, including bleeding symptoms, laboratory test results, disease classification, and treatment approaches. The results of this study are expected to improve understanding of von Willebrand disease in children in this region and support better diagnostic and therapeutic planning for affected patients.
Inclusion: Age 0-18 years; Residents of Assiut Governorate or receiving care at Assiut University Children's Hospital; Suspected or confirmed von Willebrand disease (VWD) based on clinical bleeding symptoms or referral for evaluation; Patients diagnosed with VWD using standard laboratory tests, including:; VWF antigen (VWF:Ag); VWF ristocetin cofactor activity (VWF:RCo); Factor VIII activity.
Exclusion: Other inherited bleeding disorders, such as:; Platelet function disorders; Acquired bleeding disorders, including:; Liver disease; Renal insufficiency; Vitamin K deficiency; Disseminated intravascular coagulation (DIC); Use of medications that may interfere with coagulation testing (e.g., anticoagulants, antiplatelet drugs); Incomplete clinical or laboratory data (for retrospective cases); Refusal of consent for participation (for prospective cases); Hemophilia A or B; Rare coagulation factor deficiencies (e.g., factors I, V, VII, X, XI deficiency).